Literature DB >> 28581462

Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant.

R Salem1, R Massoud1, B Haffar1, R Mahfouz2, A Bazarbachi1, J El-Cheikh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28581462     DOI： 10.1038/bmt.2017.82

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview.

Authors:  E Sabattini; F Bacci; C Sagramoso; S A Pileri
Journal:  Pathologica       Date:  2010-06

2.  Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.

Authors:  Manish Sharma; Farhad Ravandi; Ulas Darda Bayraktar; Alexandre Chiattone; Qaiser Bashir; Sergio Giralt; Julianne Chen; Muzaffar Qazilbash; Partow Kebriaei; Marina Konopleva; Michael Andreeff; Jorge Cortes; Deborah McCue; Hagop Kantarjian; Richard E Champlin; Marcos de Lima
Journal:  Biol Blood Marrow Transplant       Date:  2011-07-20       Impact factor: 5.742

3.  Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

Authors:  Jan Krönke; Richard F Schlenk; Kai-Ole Jensen; Florian Tschürtz; Andrea Corbacioglu; Verena I Gaidzik; Peter Paschka; Shiva Onken; Karina Eiwen; Marianne Habdank; Daniela Späth; Michael Lübbert; Mohammed Wattad; Thomas Kindler; Helmut R Salih; Gerhard Held; David Nachbaur; Marie von Lilienfeld-Toal; Ulrich Germing; Detlef Haase; Hans-Günther Mergenthaler; Jürgen Krauter; Arnold Ganser; Gudrun Göhring; Brigitte Schlegelberger; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

4.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

Authors:  Konstanze Döhner; Richard F Schlenk; Marianne Habdank; Claudia Scholl; Frank G Rücker; Andrea Corbacioglu; Lars Bullinger; Stefan Fröhling; Hartmut Döhner
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

5.  Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.

Authors:  Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

6.  The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Authors:  Rosemary E Gale; Claire Green; Christopher Allen; Adam J Mead; Alan K Burnett; Robert K Hills; David C Linch
Journal:  Blood       Date:  2007-10-23       Impact factor: 22.113

7.  NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).

Authors:  Friederike Schneider; Eva Hoster; Michael Unterhalt; Stephanie Schneider; Annika Dufour; Tobias Benthaus; Gudrun Mellert; Evelin Zellmeier; Stefan K Bohlander; Michaela Feuring-Buske; Christian Buske; Jan Braess; Susanne Fritsch; Achim Heinecke; Maria C Sauerland; Wolfgang E Berdel; Thomas Buechner; Bernhard J Woermann; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Blood       Date:  2009-03-11       Impact factor: 22.113

8.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

Authors:  P Gorello; G Cazzaniga; F Alberti; M G Dell'Oro; E Gottardi; G Specchia; G Roti; R Rosati; M F Martelli; D Diverio; F Lo Coco; A Biondi; G Saglio; C Mecucci; B Falini
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

9.  AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

Authors:  Claudia Haferlach; Cristina Mecucci; Susanne Schnittger; Alexander Kohlmann; Marco Mancini; Antonio Cuneo; Nicoletta Testoni; Giovanna Rege-Cambrin; Antonella Santucci; Marco Vignetti; Paola Fazi; Maria Paola Martelli; Torsten Haferlach; Brunangelo Falini
Journal:  Blood       Date:  2009-05-08       Impact factor: 22.113

10.  Assessment of Minimal Residual Disease in Standard-Risk AML.

Authors:  Adam Ivey; Robert K Hills; Michael A Simpson; Jelena V Jovanovic; Amanda Gilkes; Angela Grech; Yashma Patel; Neesa Bhudia; Hassan Farah; Joanne Mason; Kerry Wall; Susanna Akiki; Michael Griffiths; Ellen Solomon; Frank McCaughan; David C Linch; Rosemary E Gale; Paresh Vyas; Sylvie D Freeman; Nigel Russell; Alan K Burnett; David Grimwade
Journal:  N Engl J Med       Date:  2016-01-20       Impact factor: 91.245
View more
  1 in total

Review 1.  The role of FLT3 inhibitors as maintenance therapy following hematopoietic stem cell transplant.

Authors:  Grace Xiuqing Li; Lan Wang; Bassam Yaghmour; Giridharan Ramsingh; George Yaghmour
Journal:  Leuk Res Rep       Date:  2018-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.